Skip to main content
. 2015 Dec 29;5(2):182–191. doi: 10.1002/cam4.576

Figure 1.

Figure 1

Metastatic castration‐resistant prostate cancer (mCRPC) drug usage proportion. (A) 2000–2003 and 2004–2008 commercial claims cohortsa; (B) 1‐year cohorts from 2010 to 2013 for LOT1; (C) 1‐year cohorts from 2010 to 2013 for LOT2+. LOT1, first line of treatment; LOT2, second line of treatment; LOT2+, beyond second line of treatment. aIn each of LOT1 and LOT2 settings, mCRPC drug usage proportion for each of these agents was significantly different (P < 0.0001) comparing the 2000–2003 and 2004–2008 commercial claims cohorts. bNo other claim of an mCRPC drug ±90 days from an mCRPC drug claim.